A symphony of immunity: How HPV mRNA-LNP vaccination orchestrates systemic anti-tumor responses
Abstract
The remarkable success of mRNA vaccines in recent years has put the mRNA lipid nanoparticle (LNP) platform in the forefront of developing highly effective countermeasures against infectious diseases. Nevertheless, mRNA-LNPs have been studied for over three decades in the context of cancer therapy,1 and mRNA cancer vaccines are now being extensively pursued owing to recent advancements in this field.2,3 Although an anti-tumor effect mediated by mRNA-LNPs necessitates coordinated, multi-compartment, humoral and cellular immune responses, these crucial immune events have not been fully characterized.
Fields of Study & Subjects
Cervical Cancer and HPV Research
Immunotherapy and Immune Responses
RNA Interference and Gene Delivery
Publication details
- Journal / source
- Molecular Therapy — Nucleic Acids
- Publisher
- Elsevier BV
- Volume
- 37
- Issue
- 1
- Pages
- 102823–102823
- Publication date
- 12 January 2026
- Language
- EN